本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 贵阳朗玛信息技术股份有限公司（以下简称"公司"）第五届董事会第四 次会议通知于 2023 年 10 月 16 日以电话、邮件方式发出，会议于 2023 年 10 月 20 日下午 2 点在贵阳总部会议室以现场结合通讯方式召开。本次董事会会 议由董事长王伟先生召集和主持，会议应到董事 5 人，实到董事 5 人，公司监 事和部分高级管理人员列席了会议。会议的召集和召开符合《中华人民共和国 公司法》和《公司章程》的有关规定。 证券代码：300288 证券简称：朗玛信息 公告编号：2023-038 贵阳朗玛信息技术股份有限公司 第五届董事会第四次会议决议公告 1、第五届董事会第四次会议决议。 特此公告。 贵阳朗玛信息技术股份有限公司董事会 2023 年 10 月 20 日 二、董事会会议审议情况 1、审议通过了《关于公司 2023 年第三季度报告的议案》 经审议，董事会认为：公司编制的《2023 年第三季度报告》内容真实、准 确、完整的反映了公司 2023 年第三季度的经营状况，不存在任何虚假记载 ...

贵阳朗玛信息技术股份有限公司独立董事 关于第五届董事会第三次会议相关事项的独立意见 根据《公司法》、《深圳证券交易所创业板股票上市规则》、《上市公司独立董 事规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等有关法律、法规、规范性文件以及《贵阳朗玛信息技术股份有限公司 章程》（以下简称"《公司章程》"）、《独立董事工作制度》的相关规定，我们作为 贵阳朗玛信息技术股份有限公司（以下简称"公司"）的独立董事，本着认真、 负责、审慎的态度，仔细阅读了公司第五届董事会第三次会议的相关议案，现发 表独立意见如下： 一、关于控股股东及其他关联方占用公司资金、公司对外担保情况的独立 意见 1、报告期内，公司控股股东及其他关联方不存在违规占用公司资金的情况， 也不存在以前年度发生并累计至报告期末的控股股东、实际控制人及其他关联方 占用公司资金的情况； 2、报告期末公司对子公司实际担保余额为 4,000 万元人民币，占公司 2022 年 12 月 31 日经审计归属于母公司净资产的比例为 2.61%，均为对合并报表范围 内控股子公司的担保。公司发生的对外担保行为已按照法律、法规、《公司章程》 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 贵阳朗玛信息技术股份有限公司（以下简称"公司"）第五届董事会第三 次会议通知于 2023 年 8 月 14 日以电话、邮件方式发出，会议于 2023 年 8 月 24 日上午 10 点在贵阳总部会议室以现场方式召开。本次董事会会议由董事长 王伟先生召集和主持，会议应到董事 5 人，实到董事 5 人，公司监事和部分高 级管理人员列席了会议。会议的召集和召开符合《中华人民共和国公司法》和 《公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过了《关于公司 2023 年半年度报告及报告摘要的议案》 公司《2023 年半年度报告》及《2023 年半年度报告摘要》（公告编号： 2023-037）具体内容详见中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn），《2023 年半年度报告摘要》同时刊登于公司 指定的信息披露媒体《证券日报》。 表决结果：同意 5 票，弃权 0 票，反对 0 票。 特此公告。 证券代码：300288 证券简称：朗玛信息 ...

贵阳朗玛信息技术股份有限公司 第五届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300288 证券简称：朗玛信息 公告编号：2023-035 一、监事会会议召开情况 贵阳朗玛信息技术股份有限公司（以下简称"公司"）第五届监事会第三 次会议于 2023 年 8 月 24 日上午 11 时在贵阳总部会议室以现场结合通讯方式 召开。本次会议通知已于 2023 年 8 月 14 日送达各位监事。会议应到监事 3 人， 实际出席监事 3 人，会议由监事会主席李晓鹏先生主持，董事会秘书及证券事 务代表列席了会议。会议的召集和召开符合《中华人民共和国公司法》和《公 司章程》的有关规定。 表决结果：同意 3 票，弃权 0 票，反对 0 票。 特此公告。 贵阳朗玛信息技术股份有限公司监事会 二、监事会会议审议情况 1、审议通过了《关于公司2023年半年度报告及报告摘要的议案》 经审核，与会监事一致认为：公司2023年半年度报告全文及摘要的编制和 审核程序符合相关法律、法规的要求，报告内容真实、准确、完整地反映了公 司2023年半年度经营的 ...

2023年1月-6月非经营性资金占用及其他关联资金往来情况汇总表 | | | | | 2023年1月-6月非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 编制单位：贵阳朗玛信息技术股份有限公司 | | | | | | | | | | 单位：万元 | | 非经营性 资金占用 | 资金占用方名称 | 占用方与上市公司 的关联关系 | 上市公司核算 的会计科目 | 2023年期初 往来资金余额 | 2 0 2 3年1 - 6月往 来累计发生金额 | 2023年1-6月 往来资金的利 | 2023年1-6月 偿还累计发生 | 2023年6月30 日往来资金余 | 占用形成原因 | 占用性质 | | | | | | | （不含利息） | 息（如有） | 金 额 | 额 | | | | 控股股东、实 | | | | | | | | | | | | 际控制人及其 | | | | | | | | | | | | 附属企业 | | | | | | | | | | ...

投资者关系活动记录表 编号：2023-001 | 投资者关系 | □特定对象调研 □分析师会议 □媒体采访 ■业绩说明会 | | --- | --- | | 活动类别 | □新闻发布会 □路演活动 □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | 通过"全景路演"网站参与本次业绩说明会的投资者 | | 及人员姓名 | | | 时间 | 2023 年 5 月 17 日 15:30-17:30 | | 地点 | "全景路演"（http://rs.p5w.net） | | 上市公司 | 董事、总经理王健先生，董事、董事会秘书兼财务总监王春女士， | | 接待人员姓名 | 独立董事杨小舟先生，证券事务代表肖越越女士 | | | 公司于 2023 年 5 月 17 日（星期三）15:30-17:30 参加了贵州 | | | 证监局、贵州证券业协会联合全景网举办的贵州辖区上市公司投资 | | | 者集体接待日活动暨 2022 年度业绩说明会，本次业绩说明会采用 | | | 网络远程方式，公司对投资者提出的问题进行了回答。主要问题及 | | | 回复如下： | | | 1、公司 2022 ...

证券代码：300288 证券简称：朗玛信息 公告编号：2023-027 贵阳朗玛信息技术股份有限公司 关于参加2022年度贵州辖区上市公司业绩说明会暨 投资者集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳朗玛信息技术股份有限公司（以下简称"公司"）已于2023年4月26 日在中国证监会指定的信息披露网站巨潮资讯网（www.cninfo.com.cn）披露 了《2022年年度报告》及其摘要、《2023年第一季度报告》，为加强与投资者 的交流互动，便于投资者进一步了解公司2022年度和2023年第一季度经营情况 及其他关切问题，公司将参加在贵州证监局指导下，由贵州证券业协会联合深 圳市全景网络有限公司举办的"2022年度贵州辖区上市公司业绩说明会暨投资 者集体接待日活动"，具体安排如下： 一、业绩说明会的安排 召开时间：2023年5月17日15:30-17:30 召开方式：网络远程方式 出席本次活动人员有：公司董事、总经理王健先生，董事、财务总监兼董 事会秘书王春女士，独立董事杨小舟先生。 参与方式：投资者可登陆http://rs.p5 ...

Financial Performance - The company's operating revenue for 2022 was ¥436,617,213.15, representing a 7.55% increase compared to ¥405,972,195.92 in 2021[20] - The net profit attributable to shareholders for 2022 was ¥70,288,596.14, a 10.40% increase from ¥63,669,266.10 in 2021[20] - The net profit after deducting non-recurring gains and losses was ¥67,369,279.85, up 17.18% from ¥57,489,757.08 in 2021[20] - The basic earnings per share for 2022 was ¥0.21, a 10.53% increase from ¥0.19 in 2021[20] - The total assets at the end of 2022 were ¥1,849,235,259.72, a decrease of 2.59% from ¥1,898,408,909.29 at the end of 2021[20] - The net assets attributable to shareholders at the end of 2022 were ¥1,533,587,183.58, an increase of 4.32% from ¥1,470,057,415.48 at the end of 2021[20] - The net cash flow from operating activities for 2022 was ¥73,999,859.23, a slight increase of 1.47% from ¥72,929,751.76 in 2021[20] - The weighted average return on net assets for 2022 was 4.67%, up from 4.42% in 2021[20] Revenue Breakdown - The company's medical services and health information services generated CNY 287.39 million in revenue in 2022, accounting for 65.82% of total operating revenue[31] - The revenue from mobile resale business increased by 17.94% to ¥124,192,638.32, accounting for 28.44% of total revenue[64] - The revenue from medical information services rose by 7.18% to ¥124,072,606.28, maintaining a stable contribution of 28.42% to total revenue[64] - The revenue from medical services was ¥163,315,873.02, showing a slight increase of 1.79% compared to the previous year[64] - The pharmaceutical e-commerce segment generated operating revenue of 2.66 billion yuan in 2022, down 6.41% from the previous year due to industry policy impacts[51] - The telecommunications resale business achieved revenue of 124.20 million yuan in 2022, reflecting a growth of 17.90% year-on-year[52] Market Trends - The internet healthcare market in China is projected to grow from CNY 196.1 billion in 2020 to CNY 577.8 billion by 2025, reflecting a compound annual growth rate of 31.79%[32] - The telecommunications industry in China achieved a revenue of CNY 1.58 trillion in 2022, marking an 8.0% increase from the previous year[36] - The number of mobile phone users in China reached 1.683 billion by the end of 2022, with a net increase of 40.62 million users[37] Strategic Initiatives - The company continues to deepen its "Internet + Medical" strategy, integrating online medical services with offline hospital services, leading to steady growth and enhanced competitiveness[40] - The company is enhancing its operational efficiency through the development of artificial intelligence models and digital asset platforms for doctors[50] - The company is focusing on the development of artificial intelligence in the medical field, leveraging over 10 years of accumulated medical data and advanced algorithms[101] - The company aims to achieve profitability in internet healthcare by exploring innovative business models and promoting services in grassroots medical institutions across the country[102] - The company is committed to upgrading medical information systems and infrastructure at its affiliated hospitals to improve service quality and expand its brand influence[106] Research and Development - Research and development expenses decreased by 7.55% to ¥28,562,253.77 compared to the previous year[75] - R&D expenditure amounted to ¥28,562,253.77 in 2022, accounting for 6.54% of operating revenue, down from 7.61% in 2021[82] - The number of R&D personnel decreased to 123 in 2022 from 193 in 2021, representing a decline of 36.27%[82] - The company has developed a system for intelligent analysis of operational data for quick application products, providing valuable insights for business decisions[81] Governance and Compliance - The company has established a performance evaluation and incentive system for its executives, ensuring transparency and compliance with relevant laws and regulations[113] - The board of directors consists of 5 members, including 2 independent directors, meeting legal and regulatory requirements[112] - The company maintains a complete and independent financial institution, with a dedicated accounting system and financial management policies[117] - The audit committee oversees internal and external audits, ensuring the authenticity and completeness of financial information[114] - The company has committed to timely and accurate information disclosure, ensuring equal access for all shareholders[114] Future Outlook - The financial outlook for 2023 includes a projected revenue increase of approximately 20% year-over-year[121] - The company provided a revenue guidance for 2023, expecting a growth rate of 20% compared to 2022[129] - The company plans to enhance its product offerings and invest in research and development to drive future growth[123] - The company is exploring potential mergers and acquisitions to accelerate its growth strategy[123] Employee and Compensation - The total pre-tax remuneration for directors, supervisors, and senior management in 2022 was 5.9362 million yuan[135] - The highest remuneration was received by the chairman, Wang Wei, amounting to 1.3293 million yuan[136] - The company has a clear and competitive compensation policy, including basic salary, performance bonuses, and various allowances[144] - The company has established a training program to enhance employees' professional skills and introduced internal trainers for specialized training[145] Cash Flow and Investments - Investment cash inflow increased by 12,994.60% year-on-year, primarily due to the release of previously frozen funds from a lawsuit[84] - Investment cash outflow decreased by 45.94% year-on-year, mainly due to reduced capital expenditures on construction projects[84] - Financing cash inflow decreased by 49.00% year-on-year, attributed to a reduction in bank borrowings[84] - Operating cash inflow totaled ¥465,915,789.44, a 3.50% increase from ¥450,140,505.43 in the previous year[84] Internal Control - The company has established internal controls for all business areas, achieving the goal of effective internal control without any major defects reported[151] - The self-assessment report on internal control was approved by the board, confirming that 100% of the total assets and operating income of the evaluated units are included in the consolidated financial statements[153] - There were no significant deficiencies in internal control identified during the reporting period, with zero major or important deficiencies reported in both financial and non-financial areas[154]

Financial Performance - The company's revenue for Q1 2023 was ¥106,621,778.87, representing a 3.96% increase compared to ¥102,559,778.51 in the same period last year[5] - Net profit attributable to shareholders was ¥21,263,432.84, a significant increase of 39.96% from ¥15,193,039.67 year-on-year[5] - Basic earnings per share rose to ¥0.0629, reflecting a 39.78% increase from ¥0.0450 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 106,621,778.87, an increase of 3.3% compared to CNY 102,559,778.51 in Q1 2022[25] - Net profit for Q1 2023 reached CNY 20,681,420.89, up 56.5% from CNY 13,184,313.84 in the same period last year[26] - Earnings per share (EPS) increased to CNY 0.0629 from CNY 0.0450, representing a growth of 39.1%[27] - The total comprehensive income attributable to shareholders of the parent company was CNY 21,263,432.84, compared to CNY 15,193,039.67 in the previous year, an increase of 40.0%[27] Cash Flow and Investments - The net cash flow from operating activities surged by 224.49%, reaching ¥10,517,895.97, compared to ¥3,241,332.11 in the previous year[5] - Cash flow from operating activities generated a net amount of CNY 10,517,895.97, significantly higher than CNY 3,241,332.11 in Q1 2022[28] - The net cash flow from investment activities was -6,219,657.75 CNY, indicating a significant outflow compared to the previous period's -671,698.46 CNY[29] - Cash flow from financing activities showed a net outflow of -668,376.39 CNY, compared to -101,378,831.95 CNY in the previous period[29] - The net increase in cash and cash equivalents for the quarter was 3,629,861.83 CNY, contrasting with a decrease of -98,809,198.30 CNY in the prior period[29] - The ending balance of cash and cash equivalents was 335,159,684.00 CNY, up from 283,021,459.56 CNY at the end of the previous period[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,867,402,037.41, a slight increase of 0.98% from ¥1,849,235,259.72 at the end of the previous year[5] - Total liabilities decreased to ¥285,871,594.45 from ¥288,386,237.65, a reduction of approximately 0.5%[23] - The company’s non-current assets totaled ¥1,430,903,265.00, slightly up from ¥1,427,674,436.02, reflecting a marginal increase[22] - The company’s equity remained stable at ¥337,941,402.00, unchanged from the beginning of the year[23] - The total liabilities and equity amounted to CNY 1,867,402,037.41, up from CNY 1,849,235,259.72, indicating a growth of 1.0%[24] Research and Development - Research and development expenses decreased by 40.57% compared to the same period last year, indicating a reduction in spending[12] - Research and development expenses decreased to CNY 5,071,479.88 from CNY 8,532,915.11, a reduction of 40.5%[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 38,894, with the largest shareholder holding 32.10% of the shares[15] - The company held its first temporary shareholders' meeting on March 10, 2023, successfully completing the election of the fifth board of directors and supervisory board[19] Other Notable Events - The subsidiary, Guizhou Laya Technology Co., Ltd., received medical device registration and production licenses for its blood glucose meter and test strips[18] - The company did not undergo an audit for the first quarter report, indicating that the figures are unaudited[31]